Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19204186 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | May 2025 | January 2026 | Allow | 8 | 0 | 1 | Yes | No |
| 19195185 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | April 2025 | November 2025 | Allow | 7 | 1 | 1 | No | No |
| 19072501 | HETEROCYCLIC SUBSTITUTED PYRIMIDOPYRAN COMPOUND AND USE THEREOF | March 2025 | November 2025 | Allow | 8 | 1 | 1 | No | No |
| 19009637 | TREM2 MODULATORS | January 2025 | May 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 18910967 | NOVEL COMPOUNDS | October 2024 | February 2026 | Allow | 16 | 1 | 2 | No | No |
| 18905898 | METHOD OF TREATING HAIR LOSS DISORDERS | October 2024 | March 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 18750014 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | June 2024 | March 2025 | Allow | 9 | 1 | 0 | No | No |
| 18750032 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | June 2024 | April 2025 | Allow | 10 | 1 | 0 | No | No |
| 18674233 | MIRDAMETINIB TREATMENT | May 2024 | September 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18674168 | MIRDAMETINIB TREATMENT | May 2024 | January 2025 | Allow | 8 | 1 | 0 | No | No |
| 18674104 | MIRDAMETINIB TREATMENT | May 2024 | June 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18601528 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | March 2024 | October 2024 | Allow | 7 | 0 | 1 | No | No |
| 18437335 | PRMT5 INHIBITORS AND METHODS OF USE | February 2024 | July 2024 | Allow | 5 | 0 | 0 | No | No |
| 18435939 | HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF | February 2024 | November 2025 | Allow | 21 | 2 | 0 | No | No |
| 18430205 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | February 2024 | October 2025 | Allow | 21 | 0 | 1 | No | No |
| 18430528 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | February 2024 | August 2025 | Allow | 19 | 1 | 0 | No | No |
| 18425466 | 3-(2-(6-METHOXYPYRIDIN-3-YL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTICANCER COMPOUND | January 2024 | June 2025 | Abandon | 16 | 2 | 0 | No | No |
| 18412758 | 6-AMINO-8,9-DI(4-METHOXYPHENYL)-2-OXO-3,9-DIHYDRO-2H-[1,3]THIAZOLO[5',4':5,6]PYRANO[2,3-B]PYRIDINE-7-CARBONITRILE AS ANTICANCER COMPOUND | January 2024 | June 2025 | Abandon | 17 | 2 | 0 | Yes | No |
| 18407744 | Method of Using MEK Inhibitor to Prevent Radiation Induced Fibrosis | January 2024 | January 2026 | Abandon | 24 | 0 | 1 | No | No |
| 18395741 | METHOD OF INHIBITING KINASE BY MESYLATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVES | December 2023 | September 2025 | Allow | 21 | 0 | 0 | No | No |
| 18394447 | Compounds, Compositions and Methods of Treating or Preventing Acute Lung Injury | December 2023 | October 2025 | Allow | 21 | 1 | 0 | No | No |
| 18394122 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | December 2023 | November 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18394703 | 3-(2-(4-METHOXYPYRIDIN-3-YL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTI-CANCER COMPOUND | December 2023 | June 2025 | Abandon | 17 | 2 | 0 | No | No |
| 18392493 | LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR (LHRH-R) CONJUGATES AND USES THEREOF | December 2023 | November 2025 | Allow | 23 | 1 | 1 | No | No |
| 18391420 | PHARMACOPHORE FOR TRAIL INDUCTION | December 2023 | January 2026 | Allow | 25 | 2 | 1 | No | No |
| 18538067 | JAK1 SELECTIVE INHIBITORS | December 2023 | July 2025 | Allow | 19 | 0 | 1 | No | No |
| 18529311 | PYRIDO[3',4':4,5]PYRROLO[3,2-C]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORS | December 2023 | January 2025 | Allow | 13 | 1 | 1 | No | No |
| 18526380 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | December 2023 | June 2025 | Allow | 18 | 1 | 0 | No | No |
| 18526408 | Spiropiperidine Derivatives | December 2023 | June 2025 | Allow | 18 | 1 | 0 | No | No |
| 18518127 | MIRDAMETINIB TREATMENT | November 2023 | May 2025 | Allow | 17 | 1 | 1 | No | No |
| 18508257 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | November 2023 | August 2025 | Allow | 21 | 1 | 1 | No | No |
| 18507616 | MEK INHIBITORS AND USES THEREOF | November 2023 | July 2025 | Allow | 20 | 0 | 1 | No | No |
| 18385742 | IMIDAZOPYRIDAZINE COMPOUNDS AND USES THEREOF | October 2023 | July 2025 | Allow | 20 | 0 | 1 | No | No |
| 18496034 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | October 2023 | November 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18382210 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | October 2023 | September 2025 | Allow | 23 | 0 | 0 | No | No |
| 18463865 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONISTS | September 2023 | September 2025 | Allow | 24 | 1 | 1 | No | No |
| 18549309 | ALPHA-1062 FOR TREATING TRAUMATIC BRAIN INJURY | September 2023 | December 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18459675 | IRAK4 DEGRADERS AND USES THEREOF | September 2023 | August 2025 | Allow | 23 | 1 | 0 | No | No |
| 18237152 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | August 2023 | June 2025 | Allow | 22 | 1 | 0 | No | No |
| 18233226 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | August 2023 | October 2025 | Allow | 26 | 2 | 0 | No | No |
| 18276594 | METHODS FOR TREATING COVID-19 WITH SEPIAPTERIN | August 2023 | March 2026 | Allow | 31 | 1 | 0 | No | No |
| 18225966 | THERAPEUTIC COMPOUNDS | July 2023 | June 2025 | Allow | 23 | 1 | 0 | No | No |
| 18351278 | COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR | July 2023 | October 2025 | Allow | 27 | 0 | 1 | No | No |
| 18260472 | APPLICATION OF PYRIDO[1,2-A]PYRIMIDINONE ANALOG | July 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18269193 | TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS | June 2023 | February 2026 | Allow | 32 | 0 | 0 | No | No |
| 18334976 | SOLID STATE FORMS OF SUBSTITUTED PYRAZOLOPYRIMIDINES AND USES THEREOF | June 2023 | November 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18204149 | Methods and Compositions for Treating Melanoma and Non-Melanoma Skin Cancers | May 2023 | May 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18321330 | REDUCTION OF THE INCIDENCE OR RECURRENCE OF BREAST CANCER IN POSTMENOPAUSAL WOMEN TREATED WITH INTRAVAGINAL SEX STEROID PRECURSOR | May 2023 | October 2025 | Abandon | 29 | 0 | 1 | No | No |
| 18320805 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | May 2023 | March 2025 | Allow | 22 | 1 | 1 | No | No |
| 18319509 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | May 2023 | October 2025 | Allow | 29 | 0 | 2 | Yes | No |
| 18320111 | INHIBITORS OF THE MENIN-MLL INTERACTION | May 2023 | October 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18196357 | SPIRO AROMATIC RING COMPOUND AND USE THEREOF | May 2023 | June 2025 | Allow | 25 | 1 | 1 | No | No |
| 18314913 | 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | May 2023 | May 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18143765 | CRYSTALLINE (R)-5-CARBAMOYLPYRIDIN-3-YL-2-METHYL-4-(3-(TRIFLUOROMETHOXY)BENZYL)PIPERAZINE-1-CARBOXYLATE, COMPOSITIONS AND METHODS OF USE THEREOF | May 2023 | May 2025 | Allow | 24 | 1 | 0 | No | No |
| 18311646 | Small Molecule Inhibitors of KRAS G12C Mutant | May 2023 | December 2024 | Allow | 20 | 0 | 1 | Yes | No |
| 18311639 | Small Molecule Inhibitors of KRAS G12C Mutant | May 2023 | December 2024 | Allow | 20 | 0 | 1 | Yes | No |
| 18140730 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | April 2023 | January 2025 | Allow | 21 | 1 | 0 | No | No |
| 18139859 | COMBINATION THERAPY INVOLVING DIARYL MACROCYCLIC COMPOUNDS | April 2023 | October 2025 | Abandon | 29 | 1 | 1 | Yes | No |
| 18307119 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS | April 2023 | October 2025 | Allow | 29 | 1 | 1 | No | No |
| 18135607 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | April 2023 | May 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18134843 | METALLOENZYME INHIBITORS FOR TREATING CANCERS, ALZHEIMER'S DISEASE, HEMOCHROMATOSIS, AND OTHER DISORDERS | April 2023 | February 2025 | Allow | 22 | 0 | 1 | Yes | No |
| 18131226 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | April 2023 | April 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18027049 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | March 2023 | December 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 18041864 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | February 2023 | December 2025 | Allow | 34 | 0 | 0 | No | No |
| 18169408 | BRIDGED BICYCLIC COMPOUNDS AS BTK INHIBITORS | February 2023 | January 2026 | Allow | 35 | 1 | 1 | No | No |
| 18107774 | PHARMACEUTICAL COMPOSITION CONTAINING PALBOCICLIB AND LETROZOLE | February 2023 | October 2025 | Abandon | 33 | 1 | 1 | No | No |
| 18091790 | PYRIMIDINE COMPOUND | December 2022 | October 2025 | Abandon | 34 | 1 | 1 | No | No |
| 18091653 | SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES | December 2022 | July 2025 | Abandon | 31 | 1 | 0 | Yes | No |
| 18088045 | DIHYDROINDOLIZINONE DERIVATIVE | December 2022 | March 2025 | Abandon | 27 | 0 | 1 | No | No |
| 18085018 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | December 2022 | August 2025 | Allow | 32 | 1 | 1 | No | No |
| 18011734 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF FIBROTIC DISEASE | December 2022 | February 2026 | Allow | 38 | 0 | 1 | No | No |
| 18062295 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | December 2022 | January 2025 | Allow | 25 | 0 | 1 | Yes | No |
| 18061467 | TOPICAL FORMULATIONS OF RUXOLITINIB WITH AN ORGANIC AMINE PH ADJUSTING AGENT FOR TREATMENT OF SKIN DISEASES | December 2022 | January 2026 | Allow | 38 | 1 | 1 | Yes | No |
| 18060796 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | December 2022 | February 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18070993 | THERAPEUTIC COMPOUNDS | November 2022 | October 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 17998827 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | November 2022 | January 2026 | Allow | 38 | 0 | 1 | No | No |
| 17924537 | USE OF AMINOACETONITRILE COMPOUNDS FOR THE TREATMENT OF INFECTION AND DISEASE | November 2022 | September 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17938502 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | October 2022 | March 2026 | Abandon | 41 | 1 | 2 | No | No |
| 17959799 | COMPOUNDS AND THEIR METHODS OF USE | October 2022 | February 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17907707 | Methods of Treating Coronavirus Disease 2019 | September 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17956435 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINE COMPOUNDS | September 2022 | October 2025 | Allow | 36 | 2 | 1 | No | No |
| 17914414 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | September 2022 | July 2025 | Allow | 34 | 0 | 0 | No | No |
| 17949595 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | September 2022 | September 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17946181 | HETEROCYCLIC RIP1 KINASE INHIBITORS | September 2022 | January 2025 | Allow | 28 | 1 | 1 | No | No |
| 17944151 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | September 2022 | August 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17944149 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | September 2022 | August 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17941156 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RHEUMATOID ARTHRITIS AND HEALTH FUNCTIONAL FOOD | September 2022 | March 2026 | Allow | 42 | 1 | 1 | No | No |
| 17910331 | USE OF PYRROLOPYRIMIDINE COMPOUND FOR TREATING HEMOPHAGOCYTIC SYNDROME | September 2022 | July 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17908296 | ELASTASE INHIBITOR PRODRUG AND USE THEREOF | August 2022 | June 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17822871 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | August 2022 | June 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17867229 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | July 2022 | April 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17863236 | PYRIDINIUM SALT AND PEST CONTROL AGENT | July 2022 | April 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17861023 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | July 2022 | March 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 17853904 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | June 2022 | July 2024 | Allow | 24 | 1 | 1 | No | No |
| 17788698 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | June 2022 | August 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17839215 | G1T38 SUPERIOR DOSAGE REGIMES | June 2022 | March 2025 | Allow | 33 | 1 | 1 | No | No |
| 17784551 | THIENOPYRIMIDINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17836255 | ANTIBACTERIAL COMPOUNDS | June 2022 | February 2025 | Allow | 32 | 1 | 1 | No | No |
| 17832224 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | June 2022 | July 2025 | Allow | 37 | 1 | 1 | No | No |
| 17781167 | FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF | May 2022 | June 2025 | Allow | 36 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEESER, ERICH A.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEESER, ERICH A works in Art Unit 1622 and has examined 677 patent applications in our dataset. With an allowance rate of 82.1%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 26 months.
Examiner LEESER, ERICH A's allowance rate of 82.1% places them in the 54% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by LEESER, ERICH A receive 1.08 office actions before reaching final disposition. This places the examiner in the 11% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by LEESER, ERICH A is 26 months. This places the examiner in the 75% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +19.2% benefit to allowance rate for applications examined by LEESER, ERICH A. This interview benefit is in the 62% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 44.9% of applications are subsequently allowed. This success rate is in the 95% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 69.7% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 83.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 41.1% are granted (fully or in part). This grant rate is in the 32% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 12.3% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.0% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.